396 related articles for article (PubMed ID: 16140106)
1. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
Olson KB; Hellie CM; Pienta KJ
Urology; 2005 Sep; 66(3):658. PubMed ID: 16140106
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
4. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Smith A; Kressley A; Saif MW
JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
[No Abstract] [Full Text] [Related]
5. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Marx RE; Sawatari Y; Fortin M; Broumand V
J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
[TBL] [Abstract][Full Text] [Related]
6. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
Friedrich RE; Blake FA
Anticancer Res; 2007; 27(4A):1841-5. PubMed ID: 17649782
[TBL] [Abstract][Full Text] [Related]
7. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Brown JJ; Ramalingam L; Zacharin MR
Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
[TBL] [Abstract][Full Text] [Related]
11. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.
Bagan JV; Jimenez Y; Murillo J; Hernandez S; Poveda R; Sanchis JM; Diaz JM; Scully C
Oral Oncol; 2006 Mar; 42(3):327-9. PubMed ID: 16275156
[No Abstract] [Full Text] [Related]
12. Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case.
Frei M; Bornstein MM; Schaller B; Reichart PA; Weimann R; Iizuka T
J Oral Maxillofac Surg; 2010 Apr; 68(4):863-7. PubMed ID: 20307770
[No Abstract] [Full Text] [Related]
13. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
Jimenez-Soriano Y; Bagan JV
Med Oral Patol Oral Cir Bucal; 2005 Jul; 10 Suppl 2():E88-91. PubMed ID: 15995577
[No Abstract] [Full Text] [Related]
14. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
[TBL] [Abstract][Full Text] [Related]
15. Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series.
Ferlito S; Liardo C; Puzzo S
Minerva Stomatol; 2010; 59(11-12):593-601. PubMed ID: 21217623
[TBL] [Abstract][Full Text] [Related]
16. Complication related to bisphosphonate therapy: osteonecrosis of the jaw.
Lee J
J Infus Nurs; 2009; 32(6):330-5. PubMed ID: 19918142
[TBL] [Abstract][Full Text] [Related]
17. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
Kraj M; Pogłód R; Maj S; Owczarska K
Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
[No Abstract] [Full Text] [Related]
18. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
19. Jaw complications in breast and prostate cancer patients treated with zoledronic acid.
Ortega C; Faggiuolo R; Vormola R; Montemurro F; Nanni D; Goia F; Aglietta M
Acta Oncol; 2006; 45(2):216-7. PubMed ID: 16546871
[No Abstract] [Full Text] [Related]
20. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
